Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIVAna Gonzalez‐Cordón, Juergen Rockstroh, Julie Fox et al.|Journal of Antimicrobial Chemotherapy|2021Cited by 27
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized TrialLaura Waters, Luminita Schneider, Lambert Assoumou et al.|Clinical Infectious Diseases|2022Cited by 17
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravirAna Gonzalez‐Cordón, Juergen Rockstroh, Lambert Assoumou et al.|Journal of Antimicrobial Chemotherapy|2023Cited by 2